top of page

Latest News

Aug 23, 2023

siRNAgen Therapeutics Announces the Appointment of Renowned Scientific and
Strategic Advisors

siRNAgen Therapeutics, a leading biotech in the RNAi therapeutics space, is pleased to announce the expansion of its advisory board with the inclusion of distinguished scientific and strategic experts.

siRNAgen Therapeutics Announces the Appointment of Renowned Scientific and
Strategic Advisors

Aug 4, 2023

siRNAgen Therapeutics Advances SRN-001 to Phase 1a Clinical Trials

Novel siRNA Immunology Drug SRN-001 Breaks New Ground in with Phase 1 Trials in Australia, Leveraging Proprietary SAMiRNA™ Technology for Extrahepatic Delivery

siRNAgen Therapeutics Advances SRN-001 to Phase 1a Clinical Trials

Nov 21, 2022

DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics

In a recent interview with DeciBio, June Park, CEO of siRNAgen, covered a wide range of topics such as the rapid growth in the siRNA market, expanding RNAi indication areas, and rise of globalization

DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics

Sep 29, 2022

siRNAgen Awarded Johnson & Johnson Innovation Seoul Innovation QuickFire Challenge

Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce siRNAgen as an Awardee of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

siRNAgen Awarded Johnson & Johnson Innovation Seoul Innovation QuickFire Challenge

Sep 15, 2022

siRNAgen Therapeutics joins Endless Frontier Labs

siRNAgen Therapeutics has been selected to join the Endless Frontier Labs 2022-2023 cohort. This year’s 75 ground-breaking companies were selected amongst a competitive pool of over 1,000 applicants. siRNAgen will be joining as one of 26 that have been selected for the Life Sciences Track.

siRNAgen Therapeutics joins Endless Frontier Labs

Strategic Advisors

Strategic Advisors
bottom of page